title: Treatment of giardiasis after nonresponse to nitroimidazole.
abstract: During January 2008-October 2013, a total of 12 cases of giardiasis at the Chaim Sheba and Shaare Zedek Medical Centers, Israel, did not respond to nitroimidazole; 83.3% were associated with travel and 33% with immunoglobulin deficiency. Among 110 published cases, the most effective treatment was quinacrine (efficacy 90%-100%), but its availability is limited.
authors.forename: Eyal
authors.initials: E
authors.lastname: Meltzer
authors.forename: Tamar
authors.initials: T
authors.lastname: Lachish
authors.forename: Eli
authors.initials: E
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D005260:Female; D016829:Giardia lamblia; D005873:Giardiasis / Q000188:drug therapy* / Q000469:parasitology*; D006801:Humans; D008297:Male; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010303:Paromomycin / Q000627:therapeutic use; D011796:Quinacrine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000977:Antiparasitic Agents; D009593:Nitroimidazoles; D010303:Paromomycin; D015766:Albendazole; D011796:Quinacrine